Transfection and transgenic mouse experiments supported an oncogenic role for cyclin D1 in breast cancer. We recently reported that noninvasive carcinoma in situ lesions of the human breast overexpress cyclin D, suggesting that this molecular event may represent a valuable target for chemoprevention. The purpose of the present series of investigations was to identify agents which could reduce the cyclin D expression of breast cells. We report that 9-cis retinoic acid (9-cis RA) and all trans retinoic acid (tRA) inhibited the cyclin D1 and D3 expression levels of human MCF-7, ZR-75 and T-47D breast carcinoma cells in vitro. Where detectable, similar trends were observed in the immortalized, HBL-100 and MCF-10A breast cell lines. Cyclin D2 was undetectable. The eect of retinoids was both dose-and time-dependent, and correlated with altered cell cycle kinetics and proliferative status. Retinoids were also found to inhibit the expression levels of other cell cycle related proteins, including Cdk2 and Cdk4, resulting in lower kinase activities. In contrast to other breast prevention studies, no synergistic eect was observed with retinoids and tamoxifen. The data indicate that retinoids can potently reduce cyclin D expression levels in a variety of breast cell lines in vitro, and suggest further consideration of this mechanism for the chemoprevention of breast cancer.
Introduction
Alterations in the expression of multiple cell cyclerelated proteins have been associated with breast cancer (Hunter and Pines, 1994) . Of these, increased expression of cyclins A, B, D and E have been reported in breast tumors or carcinoma cell lines (Buckley et al., 1993; Keyomarso and Pardee, 1993; Dutta et al., 1995; Keyomarsi et al., 1995) . Within the cyclin D family, overexpression and/or ampli®cation of cyclin D1 (Gillett et al., 1994; Zhang et al., 1994; Zuckerberg et al., 1995; Courjal et al., 1996; Michalides et al., 1996) and D3 (Bartkova et al., 1996) have been reported in cohorts of invasive breast carcinomas; increased cyclin D1 expression was correlated with the presence of estrogen receptors. Both cyclin D1 transgenic mouse data (Wang et al., 1994) and transfection experiments using the human T-47D breast carcinoma cell line supported the hypothesis that cyclin D1 may be a breast cancer oncogene. Dissenting data, which emanated from cyclin D1 transfection of human HBL-100 breast cells , may have resulted in part from concomitant increases in Cdk-cyclin inhibitor activity.
We recently conducted a molecular analysis of gene expression levels using in situ hybridization on a cohort of benign, premalignant and early carcinomatous human breast biopsy lesions. Epidemiological studies have provided quantitative risk estimates for the eventual development of invasive breast cancer after a biopsy with these lesions (DuPont and Page, 1985; Page and DuPont, 1993) . Elevated cyclin D mRNA expression in the breast lesion, as compared to normal ducts in the margin of the specimen, was infrequent in low risk lesions such as ®brocystic changes, radial scars, etc, or in proliferative lesions exhibiting normal cytology. Similar results were observed with atypical ductal hyperplasias, which confer an approximate fourfold increase in risk for invasive breast cancer. However, any form of ductal carcinoma in situ (DCIS), which confers an 8 ± 10-fold increase in risk, was characterized by frequent cyclin D mRNA overexpression (Weinstat-Saslow et al., 1995) . Similar trends at the protein level were observed by Simpson et al. (submitted for publication) . These data associate cyclin D overexpression with an increased risk for the development of invasive breast carcinoma in humans. Together with published reports indicative of a causal role in mammary carcinoma, the data suggest that cyclin D expression levels are modulated early in human neoplastic progression and may represent a useful target for the prevention of breast cancer.
While several agents have been reported to increase cyclin D expression in breast carcinoma cells, information on conditions which reduce cyclin D expression is fragmentary. Serine/threonine kinase inhibitors and the protein kinase inhibitor stausporine decreased cyclin D expression levels in MCF-7 human breast carcinoma cells (Jeoung et al., 1995) . The inhibition of breast carcinoma proliferation by antiestrogens in this same cell line was associated with decreased cyclin D expression, together with altered expression of other cell cycle related proteins (Watts et al., 1994 (Watts et al., , 1995 . A single report described the inhibition of cyclin D expression by a novel retinoid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-napthalene carboxylic acid (AHPN) (Shao et al., 1995) . Given the high degree of interest in retinoids as preventative agents for breast cancer (Costa et al., 1994; Love, 1994; Man, 1994; Dhingra, 1995; Noguchi et al., 1996) , we have investigated their in vitro eects on cyclin D expression in multiple immortalized and breast carcinoma cell lines. We report that both all trans retinoic acid (tRA) and 9-cis retinoic acid (9-cis RA) decrease cyclin D expression levels. In contrast to other breast prevention model system data no synergy was observed with the antiestrogen tamoxifen.
Results

Retinoid treatment of human breast carcinoma cell lines decreases cyclin D expression in vitro
We have asked whether retinoids exerted an eect on cyclin D expression. In the experiment shown in Figure  1 , MCF-7 human breast carcinoma cells were treated with various doses of all trans retinoic acid (tRA) for 3 days, and culture lysates assayed for expression of cyclin D proteins by Western blots. A progressive loss of cyclin D1 expression was noted with increasing tRA concentration, approaching the limit of detection at 1 mM (Figure 1a ). Cyclin D2 was undetectable in MCF-7 cell lysates, in agreement with previously published observations Gorospe et al., 1996) . Re-probing of the Western blot with antibody to cyclin D3 revealed a similar trend (Figure 1b ). Densitometry indicated a sixfold decrease in cyclin D3 expression at 1 mM tRA. As a control, the blot was stripped and rehybridized with anti-actin, and all lanes exhibited comparable levels of expression (Figure 1c ). The experiment shown on Figure 2 demonstrates that 9-cis retinoic acid (9-cis RA) also reduced cyclin D expression in MCF-7 breast carcinoma cells. At 1 mM 9-cis RA, cyclin D1 levels were reduced more than 20-fold from controls, while cyclin D3 levels were reduced to the limit of detection by densitometry. Time course studies of these eects are shown on Figure 3 . Decreased expression of cyclin D1 in response to 1 mM RA was evident after 48 h of culture, and was maintained through the 144 h study period. For cyclin D3, expression levels showed a transient increase over the ®rst 24 ± 48 h of culture with either RA, whereupon decreased expression levels were induced and maintained. These data suggest independent regulation of the two cyclin expression levels by RAs.
We have asked whether similar trends are observed in two additional human breast carcinoma cell lines. For the ZR-75 and T-47D cell lines, cyclin D1 and D3 expression was reduced in response to tRA (Figure 4 ). Treatment with 9-cis RA inhibited cyclin D1 and D3 levels in T-47D cells, but not ZR-75 cells (data not shown), suggesting the consideration of alterations in RAR family member expression or speci®c downstream signaling pathways. Inhibition of MCF-7 breast carcinoma cyclin D1 and D3 expression by 9-cis retinoic acid (9-cis RA) in vitro. MCF-7 cells were cultured with or without 0 ± 10 mM 9-cis RA for 3 days, 60 mg of lysate from each culture was electrophoresed on a 8 ± 16% SDS ± PAGE and transferred to a nitrocellulose membrane. The membrane was blotted with antibodies to cyclin D1 (a), cyclin D3 (b) and complexes detected by chemiluminescence. Data were representative of two experiments conducted In contrast to these human breast carcinoma cell lines, the overall levels of cyclin D expression were lower for the immortalized HBL-100 and MCF-10A cell lines. Cyclin D1 was undetectable on Western blots (data not shown). Cyclin D3 was low in expression but detectable, and was inhibited by tRA ( Figure 5 ) and 9-cis RA (data not shown). Thus, over a limited series of human breast cell lines and cultures, a relative elevation of cyclins D1 and D3 expression was observed in the carcinomatous lines. Where detectable, both immortalized and tumorigenic lines responded to in vitro culture with RA by decreased cyclin D expression.
We have asked whether RA treatment, under conditions that decrease cyclin D expression, exerted phenotype eects on cell cycle distribution and proliferation. MCF-7, ZR-75 and MCF-10A cells were incubated for 5 days with various concentrations of RA, the cell cycle distribution determined by¯ow cytometry (Table 1 ) and cell proliferation determined ( Figure 6 ). A relative decrease in the percentage of cells in S-phase, and a corresponding increase in the percentage of G 0 /G 1 phase cells was observed for the MCF-7 and ZR-75 cell lines, in which inhibited cyclin D expression was found. For the MCF-10A line, where overall levels of cyclin D1 and D3 were lower and inhibition by RA could only be veri®ed for cyclin D3, no changes were observed in response to RA treatment.
Eects of tamoxifen
Tamoxifen has been reported to synergistically interact with retinoids to reduce breast carcinoma cell line proliferation in vitro (Wetherall and Taylor, 1986; Fontana, 1987; Lama et al., 1996) and NMU-induced tumorigenicity in vivo (Anzano et al., 1994) . On this basis intermediate biomarker based clinical trials of tamoxifen/retinoid combinations are underway (personal communication, Drs Julia Lawrence and JoAnne Zujewski, NCI, NIH). We have therefore asked whether tamoxifen alone, or in combination with tRA or 9-cis RA altered cyclin D expression levels. Figure 7 presents a series of Western blots showing the protein expression levels of MCF-7 cells for various cell cycle regulatory components when treated with tRA, 9-cis RA, 1 mM tamoxifen, and RA/tamoxifen combinations. Both RAs decreased cyclin D1 levels to almost undetectable levels ( Figure 7a ), consistent with previous experiments. Tamoxifen alone was inhibitory for cyclin D1 expression, although the magnitude of this eect was not as great as that of the RAs over three replicate experiments. Synergy between the RAs and tamoxifen was not observed in the experiment shown or when longer chemiluminescence exposures were developed to observe fainter bands (data not shown). Data for cyclin D3 are shown on Figure 7b , and indicate similar trends. In experiments not shown, these trends for cyclins D1 and D3 were apparent on Northern blots, suggesting that the RAs and tamoxifen aect transcription rates or processing of the cyclin D mRNAs.
Other cyclin complex proteins
Cyclin D1 serves as a regulatory subunit for the cyclin dependent kinases Cdk4 and Cdk6 (Xiong et al., 1992; Hunter and Pines, 1994; Matsushime et al., 1994; Sherr, 1994) , which can kinase RB, resulting in the release of the transcription factor E2F and concomitant alterations in gene expression levels (Hunter and Pines, 1994; Sherr, 1994) . Cyclins D2, undetectable in the cell line used herein, and D3 can interact productively with Cdk4 and Cdk2, which is known to kinase histone H1 (Ewen et al., 1993) . A host of Eects of retinoic acid on immortalized human breast cell lines in vitro. HBL-100 and MCF-10A cells were treated with 0 ± 10 mM tRA for 3 days. 100 mg lysate from HBL-100 cell cultures (a) and MCF-10A cell cultures (b) was electrophoresed on a 10% SDS ± PAGE and transferred to nitrocellulose membranes. Western blots were performed using antibodies to cyclin D3 12.4 13.0 16.1 13.4 11.1 a Cells treated with or without tRA and 9-cis RA were harvested on day 5 and the cell cycle distribution was analysed by¯ow cytometry. For additional details see Materials and methods. b The values represent the percentage of cells in the indicated phase of cell cycle inhibitors including p21, p27, p16 and p15 have been described, of which p15 and p16 have been reported to be speci®c for Cdk4 (Xiong et al., 1992; Hunter and Pines, 1994; Sherr, 1994) . We have asked whether RA and tamoxifen treatment altered the expression of only cyclin D, or alternatively has eects on the relative protein expression of other components of the G 1 cell cycle machinery. Figure 7c , indicates that all treatments resulted in an approximate threefold reduction in Cdk2 expression; Figure 7d shows a trend in Cdk4 expression similar to that shown for the cyclin Ds, with a 3 ± 5-fold reduction in expression in response to RAs, twofold in response to tamoxifen and no apparent synergy. Levels of p53 and another G 1 cyclin, cyclin E, showed no signi®cant regulation in this system (Figure 7e ± f). For the inhibitors, p21 expression was also decreased by RAs, but was unaected by tamoxifen (Figure 7g ). The p16 inhibitor is mutated and undetectable in MCF-7 cells (Gorospe et al., 1996 , and data not shown). 5 cell/60 mm culture dish were treated with tRA or 9-cis RA. On day 3, the medium was replaced with fresh retinoid-containing mediium. On day 5, the cell proliferation was analysed by counting in triplicate using a hemocytometer. (e) tRA treated; (f) 9-cis RA treated To determine if this complex series of changes in G 1 cell cycle proteins has functional consequences, assays for Cdk2 and Cdk4 activity were performed. In the experiment shown on Figure 8 MCF-7 cells were treated with RAs, tamoxifen or combinations, cyclin/ Cdk/inhibitor complexes immunoprecipitated with anti-Cdk4 antibody and the immune complexes tested for phosphorylation of GST-Rb fusion protein.
Phosphorylation of GST-Rb was decreased in response to treatment with RAs to a greater extent than by tamoxifen, with no apparent synergy. These data are consistent with a functional eect of RAs, and a more limited eect of tamoxifen on cyclin D1 and Cdk4 expression. Phosphorylation of Histone H1 by anti-Cdk2 complexes immunoprecipitated from MCF-7 cells treated with RAs, tamoxifen or combinations are shown in Figure 9 as a measure of function of cyclin D3, which is able to complex with Cdk2 to phosphorylate Histone H1 (Ewen et al., 1993) . A pronounced reduction in Cdk2 activity was demonstrated by all treatments. These data more closely resemble the eect of RAs, tamoxifen and combinations on Cdk2 expression than on cyclin D3 expression, suggesting that modulation of multiple components of the cyclin D3 complex occurs, with Cdk2 being the limiting step.
Discussion
We have demonstrated that retinoids can decrease breast carcinoma cell line expression of the cyclin D family in vitro, with concomitant eects on Cdk activity, cell cycle status and proliferation. Each of three human breast carcinoma cell lines exhibited reduced cyclins D1 and D3 expression in response to either 9-cis retinoic acid (9-cis RA) or all trans retinoic acid (tRA). Time course studies showed the eect of retinoids to be stable through a 144 h period. Estrogen-dependent breast carcinoma cell lines were chosen for their less advanced phenotype with reference to the goal of chemoprevention; it is not known if these data are generalizable to breast carcinoma cells with more aggressive phenotypes, such as estrogen receptor negative or metastatically competent breast carcinoma cell lines. Two immortalized Lack of synergistic interaction between tamoxifen and retinoic acid on the expression of G 1 cell cycle regulatory proteins in MCF-7 breast carcinoma cells. MCF-7 cells were treated with or without 1 mM of tRA, 9-cis RA, tamoxifen or with combinations of retinoids and tamoxifen for 3 days. 60 mg of culture lysate was electrophoresed on a 8 ± 16% SDS ± PAGE and transferred to nitrocellulose membrane. Western blots were performed using antibodies to cyclin D1 (a), cyclin D3 (b), Cdk2 (c), Cdk4 (d), p53 (e), cyclin E (f), p21 (g). Bands were detected by chemiluminescence interaction between tamoxifen and retinoic acids on Cdk4 activity in vitro. MCF-7 cells were treated with or without 1 mM of tRA, 9-cis RA, tamoxifen or with combinations of retinoids and tamoxifen for 3 days. 500 mg of lysate from each culture was used to assay Cdk4 activity, with GST-Rb as a substrate. The Cdk4 kinase assay was performed as described in Materials and methods Lack of synergistic interaction between tamoxifen and retinoic acids on Cdk2 activity in vitro. MCF-7 cells were treated with or without 1 mM of tRA, 9-cis RA, tamoxifen or with combinations of retinoids and tamoxifen for 3 days. 500 mg of lysate from each culture was used to assay Cdk2 activity, with Histone H1 as a substrate. The Cdk2 kinase assay was performed as described in (Shao et al., 1995) , this is the ®rst demonstration of retinoid regulation of cyclin D expression and activity. The data suggest the hypothesis that retinoids may be useful in lowering breast epithelial cell cyclin D expression levels, testable by additional in vitro and in vivo experimentation. Retinoids belong to a family of vitamin A derivatives, which are naturally present in cells and play important physiological roles. It is well known that they are involved in the normal development process. Mouse teratocarcinoma cells dierentiated into parietal endoderm-like cells upon retinoic acid treatment in vitro (Strickland et al., 1980; Sporn and Roberts, 1983; Savatier et al., 1995) . Many reports demonstrated that retinoids inhibited the growth of a variety of tumors and transformed cells. Retinoids inhibited mammary carcinogenesis in animal models (Sporn and Roberts, 1983; Anzano et al., 1994; Lotan, 1996) . They have been shown to have an in vitro antiproliferative eect on human breast carcinoma cells, especially the estrogen receptor positive cell lines, linked to increased G 1 /G 0 , and decreased Sphase participation in the cell cycle (Rubin et al., 1994; Shao et al., 1995; Zhao et al., 1995; Lotan, 1996) . Mechanistically, these antiproliferative eects have been reported to result from altered expression of estrogen receptor (Rubin et al., 1994) and induction of TGF-b2 expression (Glick et al., 1989) . The potential signi®cance of the retinoids, and of the regulatory data presented herein, is suggested by the ongoing clinical investigations of N-(4 hydroxyphenyl) retinamide (4-HPR) and 9-cis retinoic acid as preventative agents for breast and other cancers (Lotan, 1996) .
Our focus on cyclin D expression and activity levels as a target for the chemoprevention of breast cancer stems from previously reported work in murine and human systems. Both transfection data and cyclin D1 transgenic mouse data support an oncogenic role for protein overexpression (Jiang et al., 1993; Hinds et al., 1994; Lovec et al., 1994) . A proliferative role for cyclin D was postulated from the transgenic mouse study, as both hyperplasias and carcinomas were developed (Wang et al., 1994) . In situ hybridization and immunohistochemical data from a breast biopsy lesion cohort provided somewhat dierent information in the human system. Increased cyclin D expression was obsserved in noncomedo and comedo ductal carcinoma in situ lesions, which confer an 8 ± 10-fold increase in risk patient development of invasive breast cancer, but not in typical or atypical hyperplasias conferring lower risks (Weinstat-Saslow et al., 1995) . Thus, increased cyclin D expression represented a molecular event predating invasive carcinoma in humans, but its role is not strictly allied with proliferation. Similar conclusions were published in cyclin D1 knockout mice, where proliferation in pregnancy but not puberty were aected (Sicinski et al., 1995) . In our experiments retinoic acid inhibition of cyclin D expression was accompanied by reduced proliferation in the breast carcinoma, but not the immortalized breast cell lines. Other phenotypes that cyclin D family members may impact include gene ampli®cation, DNA repair, and dierentiation Asano et al., 1995; Zhou et al., 1996 Zwijsen et al., 1996 . The potential eects of retinoids on cyclin D-associated nonproliferative functions in our model system represents an important avenue for future research. The data suggest that cyclin D represents an interesting target for chemoprevention research, but point to complex roles.
Another interesting area for future investigation concerns our ®nding that retinoids can modulate the expression levels of multiple cell cycle related proteins, in addition to the cyclin D family. For the MCF-7 cell line, such eects extended to Cdk2 and Cdk4. Our data indicating that retinoids inhibit Cdk2 and Cdk4 activity must therefore be interpreted as resulting from a multiplicity of modulatory events.
It has also been reported that retinoids can synergize with tamoxifen to prevent mammary cancer in the Nnitroso-N-methylurea (NMU)-induced rat mammary tumorigenesis model (Anzano et al., 1994) . 9-cis RA caused signi®cant suppression of rat NMU-induced carcinogenesis, as measured by tumor incidence, average number of tumors per rat, average tumor burden, and tumor latency. The combination of 9-cis RA with tamoxifen resulted in a doubling in the number of tumor-free animals, and a signi®cant decrease in tumor number and burden. However, in the present study, we failed to observe a synergistic eect of retinoids and tamoxifen on cyclin D expression, the expression of other cell cycle related proteins, or Cdk activity. One possible reason proposes that retinoids potently reduced cyclin D levels, and further down-regulation by potential synergizing agents would be beyond the limit of detection. Another potential explanation is that human breast cancer cell lines may dier from NMU-induced rat tumors with regard to basal cyclin D expression levels. NMU may also induce tumorigenesis by certain biochemical pathways (ras related, for instance), which may be distinct from cyclin D oncogenic pathways. The relevance and prevalence of these pathways in human breast cancer oncogenesis may represent an important determinant of the potential ecacy of tamoxifen/ retinoid combinations in a chemopreventative setting.
Materials and methods
Materials
tRA, tamoxifen, insulin, EGF were purchased from Sigma Co (St Louis, MO). 9-cis RA was kindly provided by Drs Louise H Foley and Alex Wood, Homan-LaRoche (Nutley, NJ). The retinoids and tamoxifen were dissolved in EtOH at 2 mM or 1 mM concentration, respectively, and all experiments using retinoids were performed in a lightreduced environment. [g-32 P]ATP (7000 Ci/mmol) was from ICN Biomedicals, Inc (Irvine, CA). Polyclonal antibody to cyclin D1 was purchased from Upstate Biotechnology Inc (Lake Placid, NY). Monoclonal antibodies to cyclin D1, D2, D3, p53, p16 and p21 were from Lab Vision Co (Fremont, CA). Monoclonal antibody to actin was from Oncogene Science (Cambridge, MA). GST-Rb, polyclonal antibodies to Cdk2, Cdk4, cyclin D3, p15 and monoclonal antibodies to cyclin E were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Histone H1, heat-inactivated horse serum, cholera toxin were from Gibco BRL (Grand Island, NY). Hydrocortisone was purchased from Collaborative Research (Bedford, MA).
Cell culture
MCF-7 cells from ATCC were grown in D-MEM with 10% heat inactivated fetal bovine serum, 4500 mg/L glucose, 100 U/ml penicillin and 100 mg/ml streptomcyin (Gibco BRL). T-47D and ZR-75 cells were maintained in RPMI-1640 medium with 10% heat inactivated fetal bovine serum, 25 mM HEPES, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco BRL). HBL-100 cells were grown in McCoy's 5A medium with 10% heat inactivated fetal bovine serum (Gibco BRL). MCF-10A cells from Dr Fred R Miller (Barbara Ann Kamanos Cancer Institute, Michigan) were grown in DMEM/F-12 (1 : 1) Medium supplemented with 20 mM HEPES, 5% heat inactivated horse serum, 0.1 mg/ml cholera toxin, 10 mg/ml insulin, 100 U/ml penicillin, 100 mg/ ml streptomycin, 10 ng/ml EGF, 0.5 mg/ml hydrocortisone. The cells were maintained in a humidi®ed atmosphere of 95% air and 5% CO 2 at 378C.
Cell proliferation assay
3610
3 MCF-7 or ZR-75 cells in 75 ml complete medium were aliquoted into each well of 96-well plates. The cells were grown overnight after which serial dilutions of tRA or 9-cis RA in 25 ml were added to a ®nal concentration of 0 ± 10 mM. Retinoid-containing medium was replaced on day 3 of the treatment. On day 5, the cell proliferation was evaluated using the Cell Titer 96 TM kit according to the manufacturer's instructions (Promega, Madison, WI). Brie¯y, on day 5, 15 ml of the tetrazolium dye solution was added to each well, and incubated for 2 h at 378C. Then 100 ml of a Solubilization/Stop solution was added to each well. After incubation at room temperature for 17 h, the absorbance at 562 nm was measured using a Kinetic Microplate Reader from Molecular Devices Co. For the proliferation assay of MCF-10A cells, 1610 5 cells were grown in 60 mm culture dishes overnight. The cells were cultured with tRA or 9-cis RA in various concentrations as above. On day 3, medium was replaced with fresh retinoidcontaining medium and on day 5, the cells were trypsinized and counted in triplicate using a hemocytometer.
Cell cycle analysis
Approximately 1610 5 cell/60 mm tissue culture dish of MCF-7, ZR-75 and MCF-10A cells were grown overnight and were cultured with tRA or 9-cis RA in various concentrations. On day 3 of treatment, the medium was replaced with fresh retinoids. The cells were trypsinized on day 5 and were washed once with D-PBS (Gibco, BRL) containing 1% FCS. The cells were used immediately or stored at 7808C before being analysed for the cell cycle distribution by¯ow cytometry using propidium iodide staining for DNA content on a Becton Dickinson FACScan ow cytometer (Wersto and Stetler-Stevenson, 1995) .
Western blot analysis
± 4610
6 cells per 100 mm dish of MCF-7 cells and T-47D, ZR-75, MCF-10A and HBL-100 cells, cultured at concentrations of 0.5 ± 1610 6 cells per 60 mm tissue culture dish, were treated on day 2 with 0 ± 10 mM of tRA or 9-cis RA for 3 days. For time course experiments, 2610 6 MCF-7 cells per 100 mm tissue culture dish were cultured for varying times with 1 mM tRA or 9-cis RA. On day 3 of treatment, retinoid-containing medium was replaced and cells were maintained for 4 or 5 days before lysis. To compare the eect of retinoids with tamoxifen, 2 ± 4610 6 MCF-7 cells in 100 mm dish were grown overnight and treated with 1 mM tRA/9-cis RA and tamoxifen, alone or combined, for 3 days. For all Western blot experiments the cells were rinsed twice with ice cold PBS and scraped into PBS containing 1 mM PMSF, 5 mg/ml aprotinin, 5 mg/ml pepstatin, 10 mg/ml trypsin inhibitor and 5 mM EDTA. After centrifugation, the cell pellets were lysed in lysis buer 1 (PBS containing 1% NP-40, 0.02% NaN 3 ) with 1 mM PMSF, 5 mg/ml aprotinin, 5 mg/ml pepstatin, 10 mg/ ml trypsin inhibitor and 5 mM EDTA. The cell lysates were subjected to three rounds of freeze-thawing, incubated on ice for 15 min and cleared by centrifugation at 48C. After quantitation of protein using a BCA reagent (Pierce, Rockford IL), the cell lysates were mixed with 46 Laemmli sample buer and boiled for 5 min. Cellular extracts equivalent to 60 mg protein from each treatment were resolved on a 8 ± 16% SDS ± PAGE and were transferred to a nitrocellulose membrane (Schleicher and Schuell, Keene, NH). Western blotting was performed using 1 mg/ml antibodies incubated overnight at 48C. The primary antibody was detected by horse radish peroxidase conjugated protein G (for polyclonal antibody), goat anti mouse IgG (for mouse monoclonal IgG antibody) or goat anti mouse IgM (for mouse monoclonal IgM antibody). The immune complex was detected by chemiluminescence reagent (Renaissance TM , DuPont NEN, Boston, MA).
Cdk2 and Cdk4 assay
For Cdk4 assays (Matsushime et al., 1994) , MCF-7 cells cultured with or without tRA/9-cis RA, tamoxifen or combinations for 3 days were rinsed twice with ice cold PBS and directly lysed in lysis buer 2 (50 mM HEPES, pH 7.5 containing 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 0.1% Tween-20 and 10% glycerol) with 1 mM DTT, 0.1 mM PMSF, 5 mg/ml pepstatin, 1 mM NaF, 10 mg/ml aprotinin, 10 mM b-glycerophosphate and 0.1 mM Na vanadate. Lysates were passed through a 25 gauge needle repeatedly and set on ice for 15 min before centrifugation. 500 mg supernatant from each lysate was incubated with 2 mg antibody to Cdk4 or control rabbit antibody to BSA, which had been precoated to 40 ml protein A-sepharose beads (Pharmacia LKB), for 3 h at 48C. The beads were washed twice with lysis buer 2, and four times with Rb kinase buer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 ) with 1 mM DTT. The beads were then resuspended in 20 ml Rb kinase buer, containing 1 mM DTT, 10 mM b-glycerophosphate, 0.1 mM Na vanadate, 1 mM NaF, 20 mM ATP, 10 mCi [g-32 P]ATP and 0.45 mg GST-Rb. After incubation at 308C for 30 min, the reactions were stopped by Laemmli sample buer.
For the Cdk2 assay (Gorospe et al., 1996) , cultured MCF-7 cells were rinsed twice in ice cold PBS and lysed in lysis buer 3 (50 mM Tris-HCl, pH 7.5 containing 250 mM NaCl, 0.1% Triton X-100) with 0.1 mM PMSF, 5 mg/ml pepstatin, 1 mM NaF, 10 mg/ml aprotinin, 10 mM b-glycerophosphate, 0.1 mM Na vanadate and 1 mM EDTA. The lysates were passed through a 25 gauge needle repeatedly, incubated on ice for 15 min, and cleared by centrifugation. 500 mg lysates were incubated with 2 mg antibody to Cdk2 or control rabbit IgG, which had been precoated to Protein A-sepharose beads (Pharmacia LKB), for 3 h at 48C. The beads were then washed twice in lysis buer 3 without any additives and four times with Histone kinase buer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 ) with 1 mM DTT. The beads were then resuspended in 20 ml Histone H1 kinase buer containing 1 mM DTT, 20 mM ATP, 2 mM EGTA, 10 mCi [g-32 P]ATP and 5 mg Histone H1. The reaction proceeded for 30 min at 308C and stopped by Laemmli sample buer. The reaction mixtures from the Cdk2 and Cdk4 kinase assays were loaded on to a 8 ± 16% SDS ± PAGE, and the gel processed for autoradiography.
Abbreviations 9-cis RA, 9-cis retinoic acid; DCIS, ductal carcinoma in situ; EGF, Epidermal growth factor; tRA, all trans retinoic acid.
